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ABSTRACT
We performed exome-wide association studies to identify genetic variants—in 
particular, low-frequency variants with a large effect size—that confer susceptibility 
to coronary artery disease or myocardial infarction in Japanese. The exome-wide 
association studies were performed with 12,698 individuals (3488 subjects with 
coronary artery disease including 2438 with myocardial infarction, 9210 controls) 
and with the use of the Illumina HumanExome-12 DNA Analysis or Infinium 
Exome-24 BeadChip. The relation of allele frequencies for 41,339 single nucleotide 
polymorphisms that passed quality control to coronary artery disease or myocardial 
infarction was examined with Fisher’s exact test. The exome-wide association study 
for coronary artery disease revealed that 126 single nucleotide polymorphisms were 
significantly (P <1.21 × 10–6) associated with this condition. Multivariable logistic 
regression analysis with adjustment for age, sex, and the prevalence of hypertension, 
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diabetes mellitus, and dyslipidemia showed that six of these polymorphisms were 
related (P < 0.01) to coronary artery disease, but none was significantly (P < 9.92 × 
10–5) associated with this condition. The exome-wide association study for myocardial 
infarction revealed that 114 single nucleotide polymorphisms were significantly 
(P <1.21 × 10–6) associated with this condition. Multivariable logistic regression 
analysis with adjustment for covariates revealed that nine of these polymorphisms 
were related (P < 0.01) to myocardial infarction. Among these nine polymorphisms, 
rs188212047 [G/T (L212F)] of STXBP2 was significantly (dominant model; P = 4.84 
× 10–8; odds ratio, 2.94) associated with myocardial infarction. STXBP2 may thus be 
a novel susceptibility locus for myocardial infarction in Japanese.
INTRODUCTION
Coronary artery disease (CAD) is a serious clinical 
problem because of its large contribution to mortality. 
Disease prevention is an important strategy for reducing 
the overall burden of CAD, and the identification of 
biomarkers for disease risk is key both for risk prediction 
and for potential intervention to reduce the chance of 
future coronary events.
Recent studies have highlighted the importance of 
genetic factors and of interactions between multiple genes 
and environmental factors in CAD [1]. The heritability 
of CAD was estimated to be 40% to 50% on the basis 
of family and twin studies [2]. Recent genome-wide 
association studies (GWASs) in European ancestry 
populations [3–8], African Americans [9], or Han Chinese 
[10, 11] have identified various genes and loci that confer 
susceptibility to CAD or myocardial infarction (MI). A 
meta-analysis of GWASs for CAD in European ancestry 
populations identified 46 loci with a genome-wide 
significance level and 104 variants at a false discovery rate 
of <5% [12]. These genetic variants typically have a minor 
allele frequency (MAF) of ≥5% and a small individual 
effect size, and they collectively account for only ~10.6% 
of the heritability of CAD [12]. A more recent meta-
analysis for CAD among European ancestry populations 
that included low-frequency (0.5% ≤ MAF < 5%) variants 
identified 58 loci with a genome-wide significance level 
and 202 independent variants at a false discovery rate of 
<5% [13]. These genetic variants together account for 
~28% of the heritability of CAD, showing that genetic 
susceptibility to this condition is largely determined 
by common variants with small effect sizes [13, 14]. 
Although several polymorphisms have been found to be 
significantly associated with MI in Japanese individuals 
[15, 16], genetic variants including low-frequency and rare 
variants, that contribute to genetic susceptibility to CAD 
or MI in Japanese remain to be identified definitively.
We have now performed exome-wide association 
studies (EWASs) with the use of exome array–based 
genotyping methods in order to identify genetic variants—
in particular, low-frequency or rare coding variants with 
moderate to large effect sizes—that confer susceptibility 
to CAD or MI in Japanese. Given that most low-
frequency or rare variants were not included in GWAS 
arrays of previous studies, we used Illumina arrays that 
provide coverage of putative functional single nucleotide 
polymorphisms (SNPs) in entire exons including low-
frequency and rare variants.
RESULTS
Characteristics of subjects
The characteristics of the 12,698 subjects enrolled 
in the study are shown in Table 1. Age, the frequency 
of men, body mass index, and the prevalence of 
hypertension, diabetes mellitus, dyslipidemia, chronic 
kidney disease, and hyperuricemia as well as systolic 
blood pressure, fasting plasma glucose level, blood 
glycosylated hemoglobin (hemoglobin A1c) content, and 
serum concentrations of triglycerides, creatinine, and 
uric acid were greater, whereas serum concentrations of 
high density lipoprotein (HDL)–cholesterol and estimated 
glomerular filtration rate (eGFR) were lower, in subjects 
with CAD or MI than in controls.
EWAS for CAD
We examined the relation of allele frequencies of 
41,339 SNPs that passed quality control to CAD with 
the use of Fisher’s exact test. A Manhattan plot for the 
EWAS of CAD is shown in Supplementary Figure 1A. 
After Bonferroni’s correction, 126 SNPs were significantly 
(P < 1.21 × 10–6) associated with CAD (Supplementary 
Table 1). The genotype distributions of these SNPs were in 
Hardy-Weinberg equilibrium (P > 0.001) among controls 
(Supplementary Table 2).
Multivariable logistic regression analysis of the 
relation of SNPs to CAD
The relation of the 126 identified SNPs to CAD 
was further examined by multivariable logistic regression 
analysis with adjustment for age, sex, and the prevalence 
of hypertension, diabetes mellitus, and dyslipidemia 
(Supplementary Table 3). Six SNPs were related (P < 0.01 
in at least one genetic model) to CAD (Table 2), but none 
of these polymorphisms showed a significant [P < 9.92 × 
10–5 (0.05/504)] association with this condition.
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EWAS for MI
We next examined the relation of allele frequencies 
of the 41,339 SNPs to MI with Fisher’s exact test. 
A Manhattan plot for the EWAS of MI is shown in 
Supplementary Figure 1B. After Bonferroni’s correction, 
114 SNPs were significantly (P < 1.21 × 10–6) associated 
with MI (Supplementary Table 4). The genotype 
distributions of these SNPs were in Hardy-Weinberg 
equilibrium (P > 0.001) among subjects with MI and 
controls (Supplementary Table 5).
Table 1: Characteristics of the 12,698 study subjects
Characteristic Control Coronary artery disease P Myocardial infarction P
No. of subjects 9210 3488  2438  
Age (years) 58.8 ± 13.8 68.1 ± 13.0 <0.0001 67.0 ± 13.3 <0.0001
Sex (male/female, %) 50.4/49.6 71.5/28.5 <0.0001 74.7/25.3 <0.0001
Body mass index  
(kg/m2) 23.1 ± 3.5 23.9 ± 3.4 <0.0001 24.0 ± 3.4 <0.0001
Current or former 
smoker (%) 37.2 36.4 0.4742 38.7 0.2039
Hypertension (%) 42.4 78.1 <0.0001 76.7 <0.0001
Systolic blood pressure 
(mmHg) 125 ± 20 141 ± 26 <0.0001 140 ± 27 <0.0001
Diastolic blood 
pressure (mmHg) 75 ± 12 75 ± 15 0.7032 76 ± 16 0.1412
Diabetes mellitus (%) 14.5 51.3 <0.0001 53.1 <0.0001
Fasting plasma glucose 
(mmol/L) 5.80 ± 1.95 7.42 ± 3.26 <0.0001 7.54 ± 3.28 <0.0001
Blood hemoglobin  
A1c (%)
5.70 ± 0.93 6.70 ± 1.67 <0.0001 6.76 ± 1.66 <0.0001
Dyslipidemia (%) 57.6 79.0 <0.0001 80.0 <0.0001
Serum triglycerides 
(mmol/L) 1.38 ± 0.96 1.63 ± 1.13 <0.0001 1.60 ± 1.07 <0.0001
Serum HDL-
cholesterol (mmol/L) 1.62 ± 0.44 1.23 ± 0.38 <0.0001 1.20 ± 0.36 <0.0001
Serum LDL-
cholesterol (mmol/L) 3.13 ± 0.80 3.12 ± 0.99 0.6627 3.14 ± 0.98 0.7934
Chronic kidney  
disease (%) 18.8 37.9 <0.0001 37.9 <0.0001
Serum creatinine 
(μmol/L)
72.9 ± 68.4 94.5 ± 111.8 <0.0001 94.2 ± 101.4 <0.0001
eGFR (mL min–1  
1.73 m–2) 74.0 ± 18.1 66.6 ± 24.8 <0.0001 67.0 ± 26.1 <0.0001
Hyperuricemia (%) 16.1 23.7 <0.0001 24.3 <0.0001
Serum uric acid 
(μmol/L)
323 ± 90 348 ± 103 <0.0001 353 ± 105 <0.0001
Quantitative data are means ± SD and were compared between subjects with coronary artery disease or myocardial 
infarction and control individuals with the unpaired Student’s t test. Categorical data were compared between two groups 
with Fisher’s exact test. Based on Bonferroni’s correction, a P value of <0.0013 (0.05/38) was considered statistically 
significant. HDL, high density lipoprotein; LDL, low density lipoprotein; eGFR, estimated glomerular filtration rate.
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Multivariable logistic regression analysis of the 
relation of SNPs to MI
The relation of the 114 identified SNPs to MI was 
further examined by multivariable logistic regression 
analysis with adjustment for age, sex, and the prevalence 
of hypertension, diabetes mellitus, and dyslipidemia 
(Supplementary Table 6). Nine SNPs were related (P 
< 0.01 in at least one genetic model) to MI (Table 3). 
Among these SNPs, rs188212047 [G/T (L212F)] 
of STXBP2 (dominant and additive 1 models) was 
significantly [P < 1.10 × 10–4 (0.05/456)] associated with 
MI, with the minor T allele representing a risk factor for 
this condition.
Association of rs188212047 with MI in men 
or women
We examined the relation of rs188212047 of 
STXBP2 to MI for men (1821 subjects with MI, 4642 
controls) or for women (617 subjects with MI, 4568 
controls) separately. Multivariable logistic regression 
analysis with adjustment for age and the prevalence of 
hypertension, diabetes mellitus, and dyslipidemia revealed 
that rs188212047 was significantly associated with MI both 
for men (P = 7.66 × 10–6; odds ratio, 2.73; 95% confidence 
interval, 1.77–4.19) and for women (P = 0.0011; odds 
ratio, 3.77; 95% confidence interval, 1.76–7.54).
Relation of SNPs to intermediate phenotypes 
of MI
We examined the relation of rs188212047 
of STXBP2 and the other eight SNPs found to be 
related (P < 0.01) to MI to intermediate phenotypes 
of MI—including hypertension, diabetes mellitus, 
hypertriglyceridemia, hypo–HDL-cholesterolemia, 
hyper–low density lipoprotein (LDL)–cholesterolemia, 
chronic kidney disease, obesity, and hyperuricemia—
with the use of Fisher’s exact test or Pearson’s chi-
square test. No significant association was apparent 
between any of these SNPs and intermediate phenotypes 
(Supplementary Table 7).
Relation of chromosomal loci, genes, and SNPs 
identified in the present study to phenotypes 
previously examined in GWASs
We examined the 15 loci, genes, and SNPs 
identified in the present study to phenotypes previously 
examined by GWASs available in public databases 
[GWAS Catalog (http://www.ebi.ac.uk/gwas) and GWAS 
Central (http://www.gwascentral.org/browser)]. None of 
these loci, genes, or SNPs was found to be associated 
with CAD or MI in previous GWASs (Supplementary 
Table 8).
Table 2: Relation of single nucleotide polymorphisms (SNPs) to coronary artery disease as determined by 
multivariable logistic regression analysis
SNP  
Dominant Recessive Additive 1 Additive 2
P OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI)
rs58098972 A/G 0.0064 1.16 (1.04–1.29) 0.2601  0.0118
1.15 (1.03–
1.29) 0.1780  
rs77336780
C/G 
(A304G) 0.0355
0.90 (0.81–
0.99) 0.0145
0.74 (0.57–
0.94) 0.1381  0.0085
0.72 (0.55–
0.92)
rs200121865
G/C 
(G149A) 0.0034
2.27 (1.32–
3.86)
0.0682  0.0065 2.16 (1.25–
3.69)
0.0679  
rs202069030
G/C 
(R51S) 0.0099
0.32 (0.09–
0.78)
ND  0.0099 0.32 (0.09–
0.78)
ND  
rs7188 T/G 0.5784  0.0009 0.76 (0.64–0.89) 0.6171  0.0025
0.77 (0.65–
0.91)
rs2271395
A/G 
(T1587A)
0.0023 0.85 (0.77–0.94) 0.0918  0.0084
0.86 (0.77–
0.96)
0.0052 0.82 (0.72–0.94)
Multivariable logistic regression analysis was performed with adjustment for age, sex, and the prevalence of hypertension, 
diabetes mellitus, and dyslipidemia. Based on Bonferroni’s correction, a P value of <9.92 × 10–5 (0.05/504) was considered 
statistically significant. OR, odds ratio; CI, confidence interval; ND, not determined.
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DISCUSSION
We have now shown that rs188212047 [G/T 
(L212F)] of STXBP2 was significantly associated with MI 
in Japanese, with the minor T allele representing a risk 
factor for this condition. This SNP was associated with 
MI both in men and in women. We also identified an 
additional six and eight SNPs as candidate loci for CAD 
and MI, respectively.
The syntaxin binding protein 2 gene (STXBP2) is 
located at chromosomal region 19p13.2 (NCBI Gene, 
https://www.ncbi.nlm.nih.gov/gene) and is expressed 
in various tissues and organs including vascular 
smooth muscle (The Human Protein Atlas, http://www.
proteinatlas.org). STXBP2 is a cytosolic protein that 
interacts with syntaxin-1A, -1B, -2, and -3 [17] and 
functions in intracellular trafficking and control of 
soluble NSF attachment protein receptor (SNARE) 
complex assembly [17]. It plays a role in exocytosis 
from mast cells and neutrophils as well as in the release 
of cytotoxic granules by natural killer (NK) cells [17–
19]. Mutations in STXBP2 are associated with familial 
hemophagocytic lymphohistiocytosis (FHL), a life-
threatening hyperinflammatory syndrome that results from 
an uncontrolled and ineffective immune response due to 
dysfunction of cytotoxic T lymphocytes (CTLs) and NK 
cells [18–20]. The defect in cytotoxic activity prevents 
efficient removal of antigens and down-regulation of the 
immune response, resulting in sustained activation and 
proliferation of CTLs and NK cells [21]. The persistently 
activated CTLs and NK cells produce large amounts 
of cytokines and thereby give rise to the activation of 
histiocytes (macrophages and dendritic cells). These 
latter cells in turn migrate to sites occupied by CTLs 
and NK cells and further promote their activation, tissue 
infiltration, and secretion of inflammatory cytokines 
[22]. Organ infiltration by activated lymphocytes and 
histiocytes and the hypercytokinemia generated by these 
cells thus play a key role in the pathogenesis of FHL [23].
We have now shown that rs188212047 [G/T 
(L212F)] of STXBP2 was significantly associated with 
MI, with the minor T allele representing a risk factor 
this condition. Given that vascular inflammation is an 
important contributor to the development of coronary 
atherosclerosis and thrombosis [24, 25] and that STXBP2 
is implicated in the regulation of inflammation and the 
immune response [18–23], the association of rs188212047 
[G/T (L212F)] of STXBP2 with MI might be attributable 
to the effect of this gene on vascular inflammation.
Table 3: Relation of single nucleotide polymorphisms (SNPs) to myocardial infarction as determined by 
multivariable logistic regression analysis
SNP  
Dominant Recessive Additive 1 Additive 2
P OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI)
rs202103723
C/A 
(P511Q) 0.0006
2.68 (1.54–
4.58) 0.0448 >100 (ND) 0.0015
2.54 (1.44–
4.37)
0.0443 >100 (ND)
rs188212047
G/T 
(L212F)
4.84 × 
10–8
2.94 (2.02–
4.24) ND  
4.84 × 
10–8
2.94 (2.02–
4.24) ND  
rs1265110 G/A 0.0005 0.82 (0.74–0.92) 0.0719  0.0020
0.83 (0.74–
0.94) 0.0114
0.77 (0.62–
0.94)
rs138559558 G/A (R289C) 0.9473  0.0017 >100 (ND) 0.7886  0.0017 >100 (ND)
rs11007350 C/T 0.0067 0.86 (0.77–
0.96)
0.0394 0.77 (0.60–0.99) 0.0270
0.88 (0.78–
0.99) 0.0155
0.73 (0.57–
0.94)
rs9258102 T/C 0.0010 1.25 (1.10–1.43) 0.7389  0.0010
1.26 (1.10–
1.45) 0.6189  
rs200867550
C/T 
(V874I)
0.0083 0.13 (0.01–
0.65)
ND  0.0083 0.13 (0.01–
0.65)
ND  
rs9293471 A/G 0.0344 0.89 (0.80–0.99) 0.0244
0.80 (0.66–
0.97)
0.1373  0.0100 0.77 (0.63–0.94)
rs439121 G/T 0.1481  0.0060 1.25 (1.07–
1.46)
0.5685  0.0056 1.27 (1.07–1.51)
Multivariable logistic regression analysis was performed with adjustment for age, sex, and the prevalence of hypertension, 
diabetes mellitus, and dyslipidemia. Based on Bonferroni’s correction, P values of <1.10 × 10–4 (0.05/456) were considered 
statistically significant and are shown in bold. OR, odds ratio; CI, confidence interval; ND, not determined.
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In previous meta-analyses of GWASs for CAD, 
the MAF of SNPs ranged from 3% to 48% and the 
odds ratio from 0.67 to 1.23 [11, 13]. In our study, we 
identified STXBP2 as a novel susceptibility locus for 
MI, with the allele odds ratio and MAF of rs188212047 
being 2.51 and 0.8%, respectively. This SNP is thus a 
low-frequency variant with a moderate to large effect 
size. We also detected an additional 14 candidate loci for 
CAD (rs58098972 of WDR66, rs77336780 of OR51I1, 
rs200121865 of KLHDC2, rs202069030 of DUS2, 
rs7188 of KANK2, and rs2271395 of N4BP2) or for 
MI (rs202103723 of CWH43, rs1265110 of CCHCR1, 
rs138559558 of UBXN11, rs11007350 at 10p12.2, 
rs9258102 at 6p21.3, rs200867550 of ROR2, rs9293471 
at 5q14, and rs439121 at 6p21.3). Although rs58098972 
(allele odds ratio, 1.08; MAF, 14.5%), rs77336780 (0.94; 
20.6%), rs7188 (0.93; 32.3%), rs2271395 (0.91; 45.9%), 
rs1265110 (0.87; 30.2%), rs11007350 (0.90; 23.8%), 
rs9258102 (1.20; 10.8%), rs9293471 (0.93; 30.4%), 
and rs439121 (1.10; 35.0%) were common variants 
[rs138559558 (1.08; 1.2%) was low-frequency variant] 
with small effect sizes, rs200121865 (2.06; 0.3%), 
rs202069030 (0.10; 0.4%), rs202103723 (2.63; 0.3%), 
and rs200867550 (0.22; 0.2%) were rare variants with 
moderate to large effect sizes. Previous GWASs [3–6] 
and a meta-analysis of GWASs [12] have implicated 
chromosome 9p21.3 (CDKN2B-AS1) in predisposition 
to CAD or MI in Caucasian populations. None of the 
SNPs at this locus (rs10757274, rs2383206, rs2383207, 
rs10757278, rs1333049, rs1333045) were included in the 
human exome arrays we used.
There are several limitations to our study: (i) Given 
that the results were not replicated, their validation will 
be necessary in other independent subject panels or in 
other ethnic groups. (ii) It is possible that rs188212047 
of STXBP2 is in linkage disequilibrium with other 
polymorphisms in the same gene or in other nearby genes 
that are actually responsible for the development of MI. 
(iii) The functional relevance of rs188212047 to the 
pathogenesis of MI remains to be elucidated.
In conclusion, rs188212047 of STXBP2 may be a 
susceptibility locus for MI in Japanese. Determination 
of genotypes for this SNP may prove informative for 
assessment of the genetic risk for MI in Japanese.
MATERIALS AND METHODS
Study subjects
A total of 12,698 Japanese (3488 subjects with 
CAD, including 2438 with MI; 9210 controls) was 
examined. The subjects were recruited from individuals 
either who visited outpatient clinics of or were admitted to 
participating hospitals (Gifu Prefectural Tajimi Hospital, 
Tajimi; Gifu Prefectural General Medical Center, Gifu; 
Japanese Red Cross Nagoya First Hospital, Nagoya; Inabe 
General Hospital, Inabe; Hirosaki University Hospital 
and Hirosaki Stroke Center, Hirosaki, Japan) because 
of various symptoms or for an annual health checkup 
between 2002 and 2014; who were community-dwelling 
individuals recruited to a population-based cohort study 
in Inabe between 2010 and 2014 or in Tokyo or Kusatsu 
between 2011 and 2015; or who underwent autopsy at the 
Tokyo Metropolitan Geriatric Hospital from 1995 to 2012.
The diagnosis of CAD was based on the detection 
of stenosis of >50% in any major coronary artery or in the 
left main trunk by coronary angiography. The diagnosis 
of MI was based on typical electrocardiographic changes 
and on increases both in the serum activity of creatine 
kinase (MB isozyme) and in the serum concentration of 
troponin T. The diagnosis was confirmed by identification 
of the responsible stenosis in any of the major coronary 
arteries or in the left main trunk by coronary angiography. 
In autopsy cases, the diagnosis was pathologically 
confirmed by the detection of myocardial necrosis and the 
responsible stenosis in any of the major coronary arteries 
or in the left main trunk. The control individuals had no 
history of MI, CAD, aortic aneurysm, or peripheral artery 
disease; of ischemic or hemorrhagic stroke; or of other 
atherosclerotic, thrombotic, embolic, or hemorrhagic 
disorders. Autopsy cases were excluded from controls. 
Although some control individuals had conventional 
risk factors for CAD—including hypertension (systolic 
blood pressure of ≥140 mmHg, diastolic blood pressure 
of ≥90 mmHg, or taking of anti-hypertensive medication), 
diabetes mellitus (fasting blood glucose concentration of 
≥6.93 mmol/L, blood glycosylated hemoglobin content of 
≥6.5%, or taking of antidiabetes medication), dyslipidemia 
(serum triglyceride concentration of ≥1.65 mmol/L, serum 
HDL-cholesterol concentration of <1.04 mmol/L, serum 
LDL-cholesterol concentration of ≥3.64 mmol/L, or taking 
of anti-dyslipidemic medication), chronic kidney disease 
[eGFR of <60 mL min–1 1.73 m–2, where eGFR (mL min–1 
1.73 m–2) = 194 × (age in years)–0.287 × (serum creatinine 
in mg/dL)–1.094 (× 0.739 if female)], and hyperuricemia 
(serum concentration of uric acid of ≥416 μmol/L)—they 
did not have cardiovascular complications.
The study protocol complied with the Declaration 
of Helsinki and was approved by the Committees on the 
Ethics of Human Research of Mie University Graduate 
School of Medicine, Hirosaki University Graduate School 
of Medicine, Tokyo Metropolitan Institute of Gerontology, 
and participating hospitals. Written informed consent was 
obtained from all subjects or families of the deceased 
subjects.
EWAS
Venous blood (5 or 7 mL) was collected into tubes 
containing 50 mmol/L ethylenediaminetetraacetic acid 
(disodium salt), peripheral blood leukocytes were isolated, 
and genomic DNA was extracted from these cells with the 
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use of a DNA extraction kit (Genomix supplied by Talent, 
Trieste, Italy; or SMITEST EX-R&D supplied by Medical 
& Biological Laboratories, Nagoya, Japan) or by standard 
protocols based on phenol-chloroform extraction and spin 
columns. In autopsy cases, genomic DNA was extracted 
from kidneys. The EWASs for CAD or MI were performed 
with 3488 CAD patients or 2438 MI patients and with 
9210 controls with the use of a HumanExome-12 v1.1 or 
v1.2 DNA Analysis BeadChip or Infinium Exome-24 v1.0 
BeadChip (Illumina, San Diego, CA, USA). These exome 
arrays include putative functional exonic variants selected 
from >12,000 individual exome and whole-genome 
sequences. The exonic content consists of ~244,000 SNPs 
representing diverse populations, including European, 
African, Chinese, and Hispanic individuals [26]. SNPs 
contained in only one of the exome arrays (~3.6% of all 
SNPs) were excluded from analysis. We performed quality 
control [27] as follows: (i) Genotyping data with a call 
rate of <97% were discarded, with the mean call rate for 
the remaining data being 99.9%. (ii) Gender specification 
was checked for each sample, and those for which gender 
phenotype in the clinical records was inconsistent with 
genetic sex were discarded. (iii) Cryptic relatedness and 
duplicate samples were checked by calculation of identity 
by descent; all pairs of DNA samples showing an identity 
by descent of >0.1875 were inspected and one sample 
from each pair was excluded. (iv) The frequency of 
heterozygosity for SNPs was calculated for all samples, 
and those with extremely low or high heterozygosity (>3 
standard deviations from the mean) were discarded. (v) 
SNPs in sex chromosomes or mitochondrial DNA were 
excluded from the analysis, as were nonpolymorphic SNPs 
or SNPs with a MAF of <0.1%. (vi) SNPs whose genotype 
distributions deviated significantly (P < 0.001) from 
Hardy-Weinberg equilibrium in controls were discarded. 
(vii) Genotype data in each EWAS were examined for 
population stratification by principal components analysis 
[28], and population outliers were excluded from the 
analysis. A two-dimensional display of the samples 
examined by such analysis is presented in Supplementary 
Figure 2. A total of 41,339 SNPs passed quality control 
and was subjected to subsequent analysis.
Statistical analysis
For analysis of the characteristics of the study 
subjects, quantitative data were compared between 
patients with CAD or MI and controls with the unpaired 
Student’s t test. Categorical data were compared between 
the two groups with Fisher’s exact test. Allele frequencies 
were estimated by the gene counting method, and Fisher’s 
exact test was applied to identify departure from Hardy-
Weinberg equilibrium. We examined the relation of allele 
frequencies of each SNP to CAD or MI with Fisher’s exact 
test. To compensate for multiple comparisons of genotypes 
with CAD or MI, we applied Bonferroni’s correction for 
statistical significance of association. Given that 41,339 
SNPs that passed quality control were examined, a P value 
of <1.21 × 10–6 (0.05/41,339) was considered statistically 
significant for each EWAS. Quantile-quantile plots for P 
values of allele frequencies in the EWAS for CAD or MI 
are shown in Supplementary Figure 3. The inflation factor 
(λ) was 1.06 for CAD and 1.16 for MI. Multivariable 
logistic regression analysis was performed with CAD or 
MI as a dependent variable and independent variables 
including age, sex (0, woman; 1, man), the prevalence of 
hypertension, diabetes mellitus, and dyslipidemia (0, no 
history of these conditions; 1, positive history), as well 
as genotype of each SNP. Genotypes of each SNP were 
assessed according to dominant [0, AA; 1, AB + BB (A, 
major allele; B, minor allele)], recessive (0, AA + AB; 
1, BB), and additive genetic models, and the P value, 
odds ratio, and 95% confidence interval were calculated. 
Additive models comprised additive 1 (0, AA; 1, AB; 0, 
BB) and additive 2 (0, AA; 0, AB; 1, BB) scenarios, which 
were analyzed simultaneously with a single statistical 
model. The relation of genotypes of SNPs to intermediate 
phenotypes was examined with Fisher’s exact test (2 × 
2) or Pearson’s chi-square test (2 × 3). Bonferroni’s 
correction was also applied to other statistical analysis 
as indicated. Statistical tests were performed with JMP 
Genomics version 6.0 software (SAS Institute, Cary, NC).
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